PL 8905
Alternative Names: PL-8905Latest Information Update: 16 Sep 2024
At a glance
- Originator Palatin Technologies
- Class Cyclic peptides; Obesity therapies
- Mechanism of Action Melanocortin type 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
- No development reported Metabolic disorders
Most Recent Events
- 09 Sep 2024 Palatin Technologies announces intention to submit an IND application for Obesity in the second half of 2025
- 09 Sep 2024 Palatin Technologies plans an IND-enabling activities of PL 8905 in Obesity in the fourth quarter of 2024
- 26 Oct 2023 No development reported - Preclinical for Metabolic disorders in USA (unspecified route)